Published in Nat Genet on September 23, 2012
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
Effect of mutation order on myeloproliferative neoplasms. N Engl J Med (2015) 5.59
Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med (2016) 4.49
Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 3.75
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A (2014) 3.39
Clonal hematopoiesis associated with Tet2 deficiency accelerates atherosclerosis development in mice. Science (2017) 2.77
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA (2015) 2.73
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood (2015) 2.46
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell (2016) 2.08
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep (2015) 1.83
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood (2014) 1.82
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood (2015) 1.52
Senescence and apoptosis block hematopoietic activation of quiescent hematopoietic stem cells with short telomeres. Blood (2014) 1.46
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med (2016) 1.42
Frequent Somatic Mutation in Adult Intestinal Stem Cells Drives Neoplasia and Genetic Mosaicism during Aging. Cell Stem Cell (2015) 1.42
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood (2013) 1.37
X chromosome regulation: diverse patterns in development, tissues and disease. Nat Rev Genet (2014) 1.36
Impact of genomic damage and ageing on stem cell function. Nat Cell Biol (2014) 1.33
Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet (2015) 1.31
Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia (2014) 1.28
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell (2015) 1.25
Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet (2014) 1.24
TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev (2015) 1.18
Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev (2015) 1.17
TET proteins and the control of cytosine demethylation in cancer. Genome Med (2015) 1.13
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today (2015) 1.12
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia (2013) 1.11
Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer. Cell Stem Cell (2015) 1.11
Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med (2013) 1.09
Mutational spectrum of adult T-ALL. Oncotarget (2015) 1.09
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia (2014) 1.08
Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev (2016) 1.08
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet (2016) 1.07
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2016) 1.05
Wnt activity and basal niche position sensitize intestinal stem and progenitor cells to DNA damage. EMBO J (2015) 1.04
Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells. Cell Stem Cell (2015) 1.04
Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia (2013) 1.00
Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime. J Med Genet (2012) 0.99
A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia (2015) 0.98
Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech (2014) 0.98
Epigenetic Control of Stem Cell Potential during Homeostasis, Aging, and Disease. Cell Stem Cell (2015) 0.94
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov (2015) 0.90
The myelodysplastic syndrome as a prototypical epigenetic disease. Blood (2013) 0.90
Application of single-cell genomics in cancer: promise and challenges. Hum Mol Genet (2015) 0.90
Clonal hematopoiesis in acquired aplastic anemia. Blood (2016) 0.89
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun (2016) 0.89
Molecular Genetic Markers in Acute Myeloid Leukemia. J Clin Med (2015) 0.88
Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. Semin Hematol (2015) 0.86
DNA methylation and hydroxymethylation in hematologic differentiation and transformation. Curr Opin Cell Biol (2015) 0.86
Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. Front Immunol (2016) 0.86
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing? Curr Hematol Malig Rep (2015) 0.85
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies. Cancer Sci (2015) 0.84
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia (2015) 0.84
Genome instability of ageing stem cells--Induction and defence mechanisms. Ageing Res Rev (2015) 0.84
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood (2016) 0.84
Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Haematologica (2014) 0.84
Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep (2013) 0.84
Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia (2013) 0.83
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Sci (2014) 0.83
The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol (2014) 0.83
Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J (2014) 0.83
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol (2016) 0.83
Perspectives and future directions for epigenetics in hematology. Blood (2013) 0.82
Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals. Leukemia (2015) 0.82
Epigenetic regulation of hematopoietic stem cell aging. Exp Cell Res (2014) 0.81
New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res (2013) 0.81
The Fanconi anemia pathway is required for efficient repair of stress-induced DNA damage in haematopoietic stem cells. Cell Cycle (2015) 0.81
A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing. Mol Cell Biol (2014) 0.81
Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat Rev Cancer (2016) 0.80
Mosaicism in health and disease - clones picking up speed. Nat Rev Genet (2016) 0.79
Sex-Specific Associations of Arsenic Exposure with Global DNA Methylation and Hydroxymethylation in Leukocytes: Results from Two Studies in Bangladesh. Cancer Epidemiol Biomarkers Prev (2015) 0.79
TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Res (2015) 0.79
I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep (2014) 0.79
MicroRNAs in Control of Stem Cells in Normal and Malignant Hematopoiesis. Curr Stem Cell Rep (2016) 0.79
DNMT3A: the DioNysian MonsTer of acute myeloid leukaemia. Ther Adv Hematol (2014) 0.78
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med (2016) 0.78
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer Discov (2017) 0.78
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia (2016) 0.77
Epigenetic Control of Haematopoietic Stem Cell Aging and Its Clinical Implications. Stem Cells Int (2015) 0.77
Epigenetics of hematopoiesis and hematological malignancies. Genes Dev (2016) 0.77
Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis. PLoS Comput Biol (2014) 0.77
Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nat Commun (2016) 0.77
DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nat Commun (2016) 0.77
The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells. Leukemia (2016) 0.77
Republished: Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime. Postgrad Med J (2013) 0.77
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer (2016) 0.77
Functions of TET Proteins in Hematopoietic Transformation. Mol Cells (2015) 0.77
Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Diagn Pathol (2016) 0.76
Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. Cancer Biol Med (2016) 0.76
Clonal reversal of ageing-associated stem cell lineage bias via a pluripotent intermediate. Nat Commun (2017) 0.75
Monitoring residual disease in the ph-negative myeloproliferative neoplasms post-allogeneic stem cell transplantation: more mutations and more methodologies. Front Oncol (2014) 0.75
Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J (2017) 0.75
Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nat Commun (2017) 0.75
Accumulation of DNA damage in the aged hematopoietic stem cell compartment. Semin Hematol (2016) 0.75
Epigenetics in Normal and Malignant Hematopoiesis: An Overview and Update 2017. Cancer Sci (2017) 0.75
Molecular landscape in acute myeloid leukemia: where do we stand in 2016. Cancer Biol Med (2016) 0.75
Sixty as the new forty: considerations on older related stem cell donors. Bone Marrow Transplant (2016) 0.75
Jumping translocations in myelodysplastic syndromes. Cancer Genet (2016) 0.75
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci U S A (2010) 3.41
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A (2011) 3.07
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood (1996) 2.73
Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol (1997) 1.83
Stem cells and the aging hematopoietic system. Curr Opin Immunol (2010) 1.60
X-inactivation analysis in the 1990s: promise and potential problems. Leukemia (1998) 1.20
RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res (2008) 62.07
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron (2011) 10.61
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol (2010) 9.24
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol (2010) 9.01
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell (2012) 6.99
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Functional and evolutionary insights into human brain development through global transcriptome analysis. Neuron (2009) 5.46
The oyster genome reveals stress adaptation and complexity of shell formation. Nature (2012) 5.30
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol (2005) 5.27
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest (2010) 4.95
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. Genome Biol (2013) 4.67
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
A molecular roadmap of reprogramming somatic cells into iPS cells. Cell (2012) 4.41
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci (2011) 4.15
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99
PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res (2009) 3.95
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. Mol Cell (2007) 3.51
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol (2012) 3.44